A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Niraparib (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms MAGNITUDE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 17 Sep 2019 According to a Janssen media release, results from this study will be presented at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain.
- 14 Feb 2019 Status changed from not yet recruiting to recruiting, according to a Janssen (The Janssen Pharmaceutical Companies of Johnson & Johnson) media release.
- 07 Dec 2018 Planned End Date changed from 25 Sep 2026 to 25 Feb 2025.